Skip to content
Home
Team
Therapies
Overview/Pipeline
IC/BPS
Alenura™
Investor
News
Contact Us
Investor Login
  • December 21, 2021

Vaneltix enters joint development agreement with Hyloris Pharmaceuticals

Home
/
Investor News
/
Vaneltix enters joint development agreement with Hyloris Pharmaceuticals
Share Post:

On Thursday, December 16, Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company (“Hyloris”) with respect to Vaneltix’s Alenura™ product candidate. Under the Joint Development Agreement, Hyloris will provide certain funding for the development of our Alenura™ product candidate in return for a profit share if and when Alenura™ is commercialized. See [the link] below to Hyloris’ press release regarding the Joint Development Agreement.

Hyloris Pharmaceuticals Press Release

There can be no assurance that the Joint Development Agreement will result in an approved product or, if Alenura™ is approved, that it will be accepted by the market or generate any level of revenues or profits. In addition, the foregoing may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. Vaneltix has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Vaneltix believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Vaneltix does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

PrevPrevious
NextNext

Stay Connected

More Updates

Vaneltix planning to enroll subjects in new round of clinical trials

On Tuesday, February 21st 2023, Bound Brook, NJ – Vaneltix Pharma, Inc. (Formerly Urigen Pharmaceuticals, Inc.; “Vaneltix” or “the Company”), a specialty pharmaceutical company focused

February 21, 2023

Closing of shareholder offering

Vaneltix announces the results of the 2020 Stockholder Offering and Bridge Loan Conversion: The company raised additional proceeds of $900,000 and all the Bridge Loans

November 25, 2020
Vaneltix Pharma, Inc.
305 E High Street, Ste. 7,
Bound Brook, NJ 08805
United States
  • Tel:

    (732) 369-5911
  • Fax:

    (732) 356-1125
  • Email:

    Info@vaneltix.com
Team
Therapies
Investor
News
Contact Us
2021 © Vaneltix. All rights reserved.
Privacy Policy
Privacy Policy
This website is created by Blink.